Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality
Por:
Riancho-Zarrabeitia, L, Martinez-Taboada, V, Rua-Figueroa, I, Alonso, F, Galindo-Izquierdo, M, Ovalles, J, Olive-Marques, A, Fernandez-Nebro, A, Calvo-Alen, J, Menor-Almagro, R, Tomero-Muriel, E, Uriarte-Isacelaya, E, Botenau, A, Andres, M, Freire-Gonzalez, M, Soler, G, Ruiz-Lucea, E, Ibanez-Barcelo, M, Castellvi, I, Galisteo, C, Vila, V, Raya, E, Narvaez-Garcia, J, Exposito, L, Hernandez-Beriain, J, Horcada, L, Aurrecoechea, E and Pego-Reigosa, J
Publicada:
1 oct 2020
Ahead of Print:
1 ago 2020
Resumen:
Introduction Antiphospholipid antibodies (aPL) have been associated with organ damage and certain features in systemic lupus erythematosus(SLE) patients. Our aim was to investigate the differences between SLE patients according to the presence of aPL and/or clinical antiphospholipid syndrome (APS). Materials and methods Patients from the RELESSER-T registry were included. RELESSER-T is a Spanish multicenter, hospital-based, retrospective, SLE registry. Results We included 2398 SLE patients, 1372 of whom were positive for aPL. Overall 1026 patients were classified as SLE, 555 as SLE-APS and817 as SLE-aPL. Regarding cardiovascular risk factors, SLE-APS patients had higher rates of hypertension, dyslipidemia and diabetes than those with SLE-aPL and SLE (p < 0.001). SLE-APS patients showed higher rates of neuropsychiatric, cardiac, pulmonary, renal and ophthalmological manifestations than the other groups (p < 0.001). SLE-APS patients presented greater damage accrual with higher SLICC values (1.9 +/- 2.2 in SLE-APS, 0.9 +/- 1.4 in SLE-aPL and 1.1 +/- 1.6 in SLE,p < 0.001) and more severe disease as defined by the Katz index (3 +/- 1.8 in SLE-APS, 2.7 +/- 1.7 in SLE-aPL and 2.6 +/- 1.6 in SLE,p < 0.001). SLE-APS patients showed higher mortality rates (p < 0.001). Conclusions SLE-APS patients exhibited more severe clinical profiles with higher frequencies of major organ involvement, greater damage accrual and higher mortality than SLE-aPL and SLE patients.
Filiaciones:
Riancho-Zarrabeitia, L:
Hosp Sierrallana, Rheumatol Dept, IDIVAL, Torrelavega, Spain
Martinez-Taboada, V:
Univ Cantabria, Hosp Univ Marques Valdecilla, IDIVAL, Santander, Spain
Rua-Figueroa, I:
Hosp Univ Doctor Negrin, Las Palmas Gran Canaria, Spain
Alonso, F:
Unidad Invest Soc Espanola Reumatol, Madrid, Spain
Galindo-Izquierdo, M:
Hosp Univ Doce Octubre, Madrid, Spain
Ovalles, J:
Hosp Gen Univ Gregorio Maranon, Madrid, Spain
Olive-Marques, A:
Hosp Badalona Germans Trias & Pujol, Catalunya, Spain
Fernandez-Nebro, A:
Hosp Univ Carlos Haya, Malaga, Spain
Calvo-Alen, J:
Hosp Univ Araba, Araba, Spain
Menor-Almagro, R:
Hosp Jerez, Andalucia, Spain
Tomero-Muriel, E:
Hosp Univ La Princesa, Madrid, Spain
Uriarte-Isacelaya, E:
Hosp Univ Donosti, Pais Vasco, Spain
Botenau, A:
Hosp Univ Ramon y Cajal, Madrid, Spain
:
Hosp Gen Univ Alicante, Valenciana, Spain
Freire-Gonzalez, M:
Hosp Univ Juan Canalejo, Coruna, Spain
Soler, G:
Hosp Marina Baixa, Valenciana, Spain
Ruiz-Lucea, E:
Hosp Univ Basurto, Pais Vasco, Spain
Ibanez-Barcelo, M:
Hosp Univ Son Llatzer, Illes Balears, Spain
Castellvi, I:
Hosp Santa Creu & Sant Pau, Catalunya, Spain
Galisteo, C:
Hosp Univ Parc Tauli, Catalunya, Spain
Vila, V:
Hosp Comarcal Monforte, Galicia, Spain
Raya, E:
Hosp Univ Clin San Cecilio, Andalucia, Spain
Narvaez-Garcia, J:
Hosp Univ Bellvitge, Catalunya, Spain
Exposito, L:
Hosp Univ Canarias, Canarias, Spain
Hernandez-Beriain, J:
Hosp Insular Univ Gran Canaria, Canarias, Spain
Horcada, L:
Complejo Hosp Univ Navarra, Pamplona, Spain
Aurrecoechea, E:
Hosp Sierrallana, Rheumatol Dept, IDIVAL, Torrelavega, Spain
Pego-Reigosa, J:
Complejo Hosp Univ Vigo IRIDIS Grp, Inst Invest Sanit Galicia IISGS, Vigo, Spain
|